0.5006

4.08% -0.0213

After Hours: .51 0.0094 +1.88%

Citius Pharmaceuticals Inc (CTXR)

Overview News Price History Option Chain Financials Why CTXR Down? Discussions Forecast Stock Split

Citius Pharmaceuticals Inc stock is traded at $0.5006, with a volume of 927.19K. It is down -4.08% in the last 24 hours and down -12.18% over the past month. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Previous Close:

$0.5219

Open:

$0.51

24h Volume:

927.19K

Relative Volume:

0.44

Market Cap:

$91.43M

Revenue:

Net Income/Loss:

$-32.54M

P/E Ratio:

-2.503

EPS:

-0.2

Net Cash Flow:

$-29.06M

1W Performance:

-9.13%

1M Performance:

-12.18%

6M Performance:

-44.21%

1Y Performance:

-26.86%

1-Day Range:

$0.49

$0.54

1-Week Range:

$0.49

$0.551

52-Week Range:

$0.48

$1.07

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name

Citius Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(908) 967-6676

Address

11 COMMERCE DRIVE, CRANFORD, NJ

Employee

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

CTXR's Discussions on Twitter

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-30-21	Initiated	Maxim Group	Buy

Citius Pharmaceuticals Inc Stock (CTXR) Latest News

01:03 AM

Post-Trade Analysis: Citius Pharmaceuticals Inc (CTXR) Climbs 0.95, Closing at 0.52 - The Dwinnex

01:03 AM

08:50 AM

Citius Pharmaceuticals Inc’s results are impressive - US Post News

08:50 AM

Sep 28, 2024

Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com South Africa

Sep 28, 2024

Sep 27, 2024

Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com Canada

Sep 27, 2024

Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com UK

Sep 27, 2024

Sep 26, 2024

Armistice Capital LLC Purchases New Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - MarketBeat

Sep 26, 2024

Sep 25, 2024

Financial Snapshot: Analyzing Citius Pharmaceuticals Inc (CTXR)’s Key Ratio Metrics - The Dwinnex

Sep 25, 2024

Sep 24, 2024

CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Sep 24, 2024

Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex

Sep 24, 2024

Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News

Sep 24, 2024

Cettire shares skyrocket - ShareCafe

Sep 24, 2024

Sep 23, 2024

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Sep 23, 2024

Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex

Sep 23, 2024

Sep 21, 2024

XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World

Sep 21, 2024

Sep 19, 2024